Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on April 15, 2025

Er-Kim Announces Exclusive Distribution Agreement with Polaris Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for  Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets

Er-Kim Announces Exclusive Distribution Agreement with Polaris Pharmaceuticals to Commercialize Pegargiminase (ADZODI) for Malignant Pleural Mesothelioma (MPM) in Multiple EMEA Markets

ATHENS, Greece and SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Er-Kim Pharmaceuticals, an international company specializing in the commercialization of novel therapies for pharmaceutical and biopharmaceutical companies, today announced it has signed a …

HealthEquity’s Expedited Claims Technology Wins Artificial Intelligence Excellence Awards

HealthEquity’s Expedited Claims Technology Wins Artificial Intelligence Excellence Awards

DRAPER, Utah, April 15, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity"), the nation’s largest Health Savings Account (HSA) administrator, has been recognized by the Business Intelligence Group for its Expedited Claims AI system …

Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

Inspira Technologies Generates First Revenues from Deployment of INSPIRA ART100 Systems

RA'ANANA, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, April 15, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced …

Ezra Appoints Dr. Danna Chung as Chief Medical Officer

Ezra Appoints Dr. Danna Chung as Chief Medical Officer

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Ezra, the healthcare AI startup revolutionizing early cancer detection through full-body MRI screening, today announced the appointment of Dr. Danna Chung as Chief Medical Officer and Medical Director. Dr. Chung …

LiveWorld Releases First-Ever AI Brand Reputation Index for Leading Pharmaceutical Brands

LiveWorld Releases First-Ever AI Brand Reputation Index for Leading Pharmaceutical Brands

CAMPBELL, Calif. and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a pioneer in social-first digital engagement and integrated human-AI solutions, today released its inaugural AI Brand Reputation Index, providing …

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

CARMEL, Ind., April 15, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and …

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura i…

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura i…

ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it was found that migraine was more severe than other types …

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

RMAT designation was granted based on promising clinical data from the ongoing Phase 1/2 trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma. RMAT designation recognizes the potential of LYL314 to address significant unmet …

US Remote Patient Monitoring Market worth US$29.13 billion by 2030 with 12.8% CAGR | MarketsandMarkets™.

US Remote Patient Monitoring Market worth US$29.13 billion by 2030 with 12.8% CAGR | MarketsandMarkets™.

Delray Beach, FL, April 15, 2025 (GLOBE NEWSWIRE) -- The global US Remote Patient Monitoring Market, valued at US$14.15 billion in 2024, is forecasted to grow at a robust CAGR of 12.8%, reaching US$29.13 billion by 2030. The growing number of elderly …

Confluent Health Honors Physical Therapy Leaders for Service to Patients and Communities

Confluent Health Honors Physical Therapy Leaders for Service to Patients and Communities

LOUISVILLE, Ky., April 15, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a nationwide network of physical and occupational therapy companies, recently celebrated local outpatient clinics and clinic directors for demonstrating exceptional leadership, community …

Parexel appoints Charlotte Moser, MD, PhD, MBA as Chief Medical Officer

Parexel appoints Charlotte Moser, MD, PhD, MBA as Chief Medical Officer

DURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Charlotte Moser, MD, PhD …

Sienna Announces April Dividend

Sienna Announces April Dividend

MARKHAM, Ontario, April 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of April 2025, representing $0 …

KFSHRC Treats Artery Blockage with Innovative Non-Surgical Technique

KFSHRC Treats Artery Blockage with Innovative Non-Surgical Technique

RIYADH, Saudi Arabia, April 15, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) has successfully treated several patients suffering from below-the-knee peripheral artery stenosis and occlusion using an innovative, …

MAPS Announces MDMA-Assisted Therapy Education Event For Ukrainian Mental Health Practitioners

MAPS Announces MDMA-Assisted Therapy Education Event For Ukrainian Mental Health Practitioners

Nearly 60 Ukrainian therapists will attend the event at no cost, learning fundamentals and best practices for psychedelic-assisted therapies More than 300 practitioners from more than 30 countries have completed MAPS’ International Therapist Education …

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to …

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava …

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial

Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to progress the trial to enrollment of 39 participants in …

Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™

Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel® Precision Radionuclide Therapy™

Kennewick, WA, April 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide Therapy™, an FDA-designated Breakthrough Device for the …

Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

Entera Bio’s EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO

JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman’s oral presentation at the 2025 World Congress on …

Biomerica Reports Third Quarter Fiscal 2025 Financial Results

Biomerica Reports Third Quarter Fiscal 2025 Financial Results

Total Revenue Increases 10% Year-Over-Year Delivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service